Midazolam nur Darreichungsform FER (N05CD08)

TENDER DESCRIPTION

The Kaufmännische Krankenkasse - KKH (hereinafter referred to as KKH) pursues the objective of concluding discount agreements under Section 130a(8), sentence 2 of SGB V for the active ingredient stated under BT-21-Lot (ATC) and, if applicable, restricting them to specific dosage forms within the scope of the so-called "Open-House procedure" with all suitable pharmaceutical companies. By stipulating uniform contractual terms and a uniform access procedure, the conclusion or accession to a discount agreement under Section 130a(8), sentence 2 of SGB V for the above-mentioned active ingredient is offered to all suitable and interested pharmaceutical companies or associations of pharmaceutical companies. Interested pharmaceutical companies may request the participation documents as well as the agreement at the contact address stated. A prerequisite for concluding an agreement is that the interested pharmaceutical company submits the requested participation documents fully completed and signed. An agreement is concluded with each pharmaceutical company that meets the participation requirements. Exclusivity is not provided. Accession and/or conclusion of the agreement may take place at…

TENDER BRIEF

TENDER DOCUMENTS